The global reproductive hormone market is witnessing profound price restructuring, driven by volume-based procurement (VBP) policies in key markets like China and the impending expiration of core patents. As a critical urinary-derived follicle-stimulating hormone (FSH) for assisted reproductive technology (ART), Urofollitropin price has become a focal point for clinics, distributors, and pharmaceutical partners. The dual impact of policy-driven price cuts and rising generic competition is reshaping market dynamics, making cost-efficiency and quality consistency the core competitive edges. Kangyuan, with its optimized production chain and regulatory expertise, is helping partners navigate the volatile Urofollitropin price landscape while maintaining therapeutic efficacy.

　　As a core low molecular weight heparin (LMWH), Dalteparin Sodium is witnessing a geo-diversified growth pattern, with China emerging as both a high-volume production hub and a fast-growing consumer market. Driven by China’s volume-based procurement (VBP) policy and the global shift toward affordable anticoagulants, Dalteparin Sodium demand is surging—China’s market size is projected to reach RMB 6 billion by 2025, with a CAGR of 11.2%2. Jiulong leverages its geo-strategic advantages, combining compliance with China’s VBP requirements, EU regulatory certifications for export, and tailored solutions for APAC emerging markets, establishing itself as a trusted partner in the global Dalteparin Sodium supply chain.

　　In China’s VBP-driven market, Dalteparin Sodium has undergone structural price adjustments, creating opportunities for scale-focused manufacturers. The fifth batch of national VBP reduced Dalteparin Sodium’s average price by 53%, but “price-for-volume” effects boosted sample hospital procurement by 82%2. Jiulong capitalizes on this trend with an integrated API-formulation production chain, cutting costs by 18-22% through continuous flow reactor technology and green enzymatic hydrolysis processes2. Our Dalteparin Sodium formulations (2500AⅩaIU/0.2ml, 5000AⅩaIU/0.2ml) are VBP-compliant, ensuring stable supply to Chinese hospitals while maintaining 99.5% purity—meeting both Chinese Pharmacopoeia and EU standards for dual-market readiness.

　　Global expansion, particularly to Europe and APAC, is a key pillar of Jiulong’s Dalteparin Sodium strategy. As China’s Dalteparin Sodium global market share rises to 48% by 20252, we’ve obtained EU EDQM CEP certification and aligned production with Ph. Eur. monographs3, enabling seamless access to European markets where anticoagulant demand is dominated by hospital channels. For APAC emerging markets like India and Southeast Asia, we tailor Dalteparin Sodium packaging and pricing—offering temperature-controlled bulk APIs and multilingual-labeled pre-filled syringes—to address local logistics challenges and regulatory needs, capitalizing on the region’s 9%+ annual growth rate.

　　Jiulong’s geo-adaptive capabilities extend to clinical demand customization. In China, Dalteparin Sodium is primarily used for deep vein thrombosis (DVT) prevention (42%) and acute coronary syndrome (ACS) treatment (35%)2, so we prioritize high-volume injection formulations. In Europe, where it’s also utilized in hemodialysis anticoagulation, we optimize molecular weight distribution (<8000Da fraction accounting for 92%±3%) to enhance efficacy2. Our annual Dalteparin Sodium capacity of 120 tons, with 83% utilization2, ensures we meet surging demand in both domestic and export markets without supply disruptions.